Abozaid G.M.; Kerr K.; McKnight A.; Al-Omar H.A.; Criteria to define rare diseases and orphan drugs: A systematic review protocol. BMJ Open 2022,12(7),e06212610.1136/bmjopen-2022-06212635906057Postma M.J.; Noone D.; Rozenbaum M.H.; Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet J Rare Dis 2022,17(1),15710.1186/s13023-022-02283-z35382853Keikhosrokiani P.; Mustaffa N.; Zakaria N.; Success factors in developing iHeart as a patient-centric healthcare system: A multi-group analysis. Telemat Inform 2018,35(4),753-77510.1016/j.tele.2017.11.006Uymaz A.O.; The shift from disease-centric to patient-centric healthcare: Assessing physicians’ intention to use AI doctors. EnvironSoc Psychol 2024,9(4),1944Aminabee S.; The future of healthcare and patient-centric care: Digital innovations, trends, and predictions Emerging Technologies for Health Literacy and Medical Practice 2024,240-26210.4018/979-8-3693-1214-8.ch012Sudhakar P.; Wellens J.; Verstockt B.; Ferrante M.; Sabino J.; Vermeire S.; Holistic healthcare in inflammatory bowel disease: Time for patient-centric approaches? Gut 2023,72(1),192-20410.1136/gutjnl-2022-32822136171081Halley M.C.; Smith H.S.; Ashley E.A.; Goldenberg A.J.; Tabor H.K.; A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nat Genet 2022,54(3),219-22210.1038/s41588-022-01027-w35256804Aiuti A.; Pasinelli F.; Naldini L.; Ensuring a future for gene therapy for rare diseases. Nat Med 2022,28(10),1985-198810.1038/s41591-022-01934-935970921Applequist J.; Burroughs C.; Merkel P.A.; Direct-to-Consumer recruitment methods via traditional and social media to aid in research accrual for clinical trials for rare diseases: Comparative analysis study. J Med Internet Res 2023,25,e3926210.2196/3926236917158Balkhi B.; Almuaither A.; Alqahtani S.; Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union. Saudi Pharm J 2023,31(9),10173810.1016/j.jsps.2023.10173837638213Timpe C.; Stegemann S.; Barrett A.; Mujumdar S.; Challenges and opportunities to include patient‐centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol 2020,86(10),2020-202710.1111/bcp.1438832441052Epps C.; Bax R.; Croker A.; Global regulatory and public health initiatives to advance pediatric drug development for rare diseases. Ther Innov Regul Sci 2022,56(6),964-97510.1007/s43441-022-00409-w35471559Vreman R.A.; de Ruijter A.S.; Zawada A.; Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discov Today 2020,25(7),1223-123110.1016/j.drudis.2020.04.01232344040Feng J.; Gao Z.; Shi Z.; Wang Y.; Li S.; Patient-reported outcomes in Gaucher’s disease: A systematic review. Orphanet J Rare Dis 2023,18(1),24410.1186/s13023-023-02844-w37626429Nguyen C.Q.; Alba-Concepcion K.; Palmer E.E.; Scully J.L.; Millis N.; Farrar M.A.; The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: A narrative review. Orphanet J Rare Dis 2022,17(1),16710.1186/s13023-022-02317-635436886Zuccato M.; Shilling D.; Fajgenbaum D.C.; The collaborative network approach: A model for advancing patient-centric research for Castleman disease and other rare diseases. Emerg Top Life Sci 2019,3(1),97-10510.1042/ETLS2018017833523193Bellgard M.I.; Sleeman M.W.; Guerrero F.D.; Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes. Health Policy Technol 2014,3(4),325-33510.1016/j.hlpt.2014.08.007Flatau T.; Greenfield J.; Dickie B.; Rayner O.; Matthews H.; Wise J.; Medical research charities and biopharmaceutical companies as partners in patient-centred RandD. Pharmaceut Med 2022,36(5),279-28610.1007/s40290-022-00442-y35953655Harnish JM; Li L; Rogic S; ModelMatcher: A scientist‐centric online platform to facilitate collaborations between stakeholders of rare and undiagnosed disease research. Hum Mutat 2022,43(6),humu.2436410.1002/humu.2436435224820Watts G.F.; Gidding S.S.; Mata P.; Familial hypercholesterolaemia: Evolving knowledge for designing adaptive models of care. Nat Rev Cardiol 2020,17(6),360-37710.1038/s41569-019-0325-831974482Alcalde-Rubio L.; Hernández-Aguado I.; Parker L.A.; Bueno-Vergara E.; Chilet-Rosell E.; Gender disparities in clinical practice: Are there any solutions? Scoping review of interventions to overcome or reduce gender bias in clinical practice. Int J Equity Health 2020,19(1),16610.1186/s12939-020-01283-432962719Halley M.C.; Halverson C.M.E.; Tabor H.K.; Goldenberg A.J.; Rare disease, advocacy and justice: Intersecting disparities in research and clinical care. Am J Bioeth 2023,23(7),17-2610.1080/15265161.2023.220750037204146Brandt M.; Johannsen L.; Inhestern L.; Bergelt C.; Parents as informal caregivers of children and adolescents with spinal muscular atrophy: A systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs. Orphanet J Rare Dis 2022,17(1),27410.1186/s13023-022-02407-535854387Ni Q.; Chen X.; Zhang P.; Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians. Orphanet J Rare Dis 2022,17(1),12910.1186/s13023-022-02279-935313924Sharma R.; Ahmed S.; Campagnari J.; Huff W.; Lloyd L.; Embedding patient-centricity by collaborating with patients to transform the rare disease ecosystem. Pharmaceut Med 2023,37(4),265-27310.1007/s40290-023-00474-y37142887Huml R.A.; Dawson J.; Bailey M.; Accelerating rare disease drug development: Lessons learned from muscular dystrophy patient advocacy groups. Ther Innov Regul Sci 2021,55(2),370-37710.1007/s43441-020-00221-432974874Monaco L.; Zanello G.; Baynam G.; Research on rare diseases: Ten years of progress and challenges at IRDiRC. Nat Rev Drug Discov 2022,21(5),319-32010.1038/d41573-022-00019-z35079160Smith J.; Damm K.; Hover G.; Chien J.; Lessons from an experiential approach to patient community engagement in rare disease. Clin Ther 2021,43(2),421-42910.1016/j.clinthera.2020.12.00233375998Bensbih S.; Souadka A.; Diez A.G.; Bouksour O.; Patient centered care: Focus on low and middle income countries and proposition of new conceptual model. J Med Surg Res 2020,7,755-76310.46327/msrjg.1.000000000000168Khanna S.; Srivastava S.; Patient-centric ethical frameworks for privacy, transparency, and bias awareness in deep learning-based medical systems. Appl Res Artif Intell Cloud Comput 2020,3(1),16-35Beier K.; Schweda M.; Schicktanz S.; Taking patient involvement seriously: A critical ethical analysis of participatory approaches in data-intensive medical research. BMC Med Inform Decis Mak 2019,19(1),9010.1186/s12911-019-0799-731023321Pergher I.; Brandolf V.P.; Pacheco D.A.J.; Vaccaro G.L.R.; A patient-centric approach to improve health care services. Cogent Busi Manag 2016,3(1),122723210.1080/23311975.2016.1227232Wan TT; Wan HS; Predictive analytics with a transdisciplinary framework in promoting patient-centric care of polychronic conditions: Trends, challenges, and solutions. AI 2023,4(3),482-9010.3390/ai4030026Sharma N.; Patient centric approach for clinical trials: Current trend and new opportunities. Perspect Clin Res 2015,6(3),134-13810.4103/2229-3485.15993626229748de Lorenzo F.; Apostolidis K.; The European Cancer Patient Coalition and its central role in connecting stakeholders to advance patient‐centric solutions in the mission on cancer. Mol Oncol 2019,13(3),653-66610.1002/1878-0261.1244830657631
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Textbook of Advanced Dermatology: Pearls for Academia and Skin Clinics (Part 2)
Women’s Health: A Comprehensive Guide to Common Health Issues in Women
Regenerative Medicine & Peripheral Nerve Endoscopy
Infectious Diseases
Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases
Lifestyle Diseases in Adolescents: Diseases, Disorders, and Preventive Measures
Lifestyle Diseases in Adolescents: Addressing Physical, Emotional, and Behavioral Issues
Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product
Precision Medicine and Human Health
Heterocyclic Anti-Inflammatory Agents: A Guide for Medicinal Chemists